Clinical Trials
Understanding Rural Health Care Systems with Pia Chowdry, MD
In this episode, host Shikha Jain, MD, speaks with Pia Chowdry, MD, about access to care in rural communities, how physicians can present information to patients and their caregivers and more.
FDA approves Zilbrysq to treat generalized myasthenia gravis
The FDA has approved UCB’s Zilbrysq for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
Twice-daily evobrutinib linked to lower relapse, less clinical worsening after 5 years
Treatment with evobrutinib in continuous, twice-daily dosing provided the lowest relapse rate and highest arrest of clinical worsening after 5 years in those with relapsing multiple sclerosis, according to data presented at ECTRIMS 2023.
Ublituximab reduced brain volume loss by 22%, suppressed new lesion formation
Treatment with ublituximab suppressed new lesion formations after 1 year while reducing thalamic volume loss and increasing T1 hypointense lesion volume compared with teriflunomide, according to data presented at ECTRIMS 2023.
Frexalimab linked to reduction in lesion activity, well tolerated in relapsing MS
In a cohort of individuals with relapsing multiple sclerosis, treatment with frexalimab significantly reduced new MRI lesions by week 24, according to a data presented at ECTRIMS 2023.
Fenebrutinib linked to reduced lesion activity, higher CSF penetration in MS at 12 weeks
In relapsing forms of multiple sclerosis, fenebrutinib treatment led to reduction of lesion activity and resulted in higher penetration into cerebrospinal fluid at 12 weeks, according to research from ECTRIMS 2023.
Immediate release formulation of investigational MS therapy has optimal results
Treatment with immediate release tablets of a non-covalent Bruton’s tyrosine kinase inhibitor for relapsing forms of multiple sclerosis met pharmacokinetic and pharmacodynamic goals, data show.
Presence of cytokines linked to NMOSD activity
Presence of cytokine proteins in those with neuromyelitis optica spectrum disorder was linked to disease activity, which was lessened after treatment with inebilizumab, according to a presentation from ECTRIMS 2023.
More positive data announced in clinical trial for myotonic dystrophy type 1 therapeutic
A Southern California biopharmaceutical company has announced positive data from a phase 1/2 clinical trial of its proprietary monoclonal antibody, AOC 1001, for those with myotonic dystrophy type 1.
Minority enrollment still low in ophthalmic clinical trials after Final Rule implemented
Race and ethnicity disclosures in clinical trials increased significantly after implementation of the Final Rule, but no progress was seen in the enrollment of minority groups, according to a poster presentation at Real World Ophthalmology.